Stocks›Healthcare›IDYA

IDYA IDEAYA Biosciences, Inc.

NasdaqResearch view

IDEAYA Biosciences, Inc. operates in the Pharmaceutical Preparations industry.

$32.85−2.95%

Oct 16 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsMid-capSEC EDGAR FY 2025-12-31

On the Wire · latest 1

All stories →

Oct 19 · PR NewswireIDEAYA and Servier present three-trial darovasertib data at ESMO 2026IDEAYA Biosciences and Servier presented ESMO 2026 data from three darovasertib trials in metastatic uveal melanoma. The results broaden the drug’s potential patient population, but clinical development and commercialization remain dependent on subsequent trial and regulatory milestones.

On the Wire · latest 1

All stories →

Oct 19 · PR NewswireIDEAYA and Servier present three-trial darovasertib data at ESMO 2026IDEAYA Biosciences and Servier presented ESMO 2026 data from three darovasertib trials in metastatic uveal melanoma. The results broaden the drug’s potential patient population, but clinical development and commercialization remain dependent on subsequent trial and regulatory milestones.

What happened

Daily closes · dots are Wire stories

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 4, 2025 and Nov 4, 2024, during the session.

Last report

Aug 4, 2026+2.01%

during the session

Last 4, next close

median 1.81% either way

up 2 of 4

Every report since 2023 →Earnings calendar →

DateEventSourceNext close

Aug 4Earnings release, during the session · 8-KSEC EDGARSEC EDGAR ↗+2.01%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

What happened · big days

19 big days in a year, and what we hold on each

A big day is a close more than 4.92% from the one before, three times IDYA’s median day (1.64%). On 0 of the 19, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.

every other trading daya big day, numbered in the list below±4.92%Hover a bar for its day. Click a big day to open it.

Shaded: since our stories began, Jun 10. Tap a bar for its day.

#DayIDYAWhat we hold that dayGroup (median of 4) · each

1 Oct 17, 2025+5.67%
Before our storiesgroup +0.8%, did not move with it
1Oct 17, 2025+5.67%
Before our stories
+0.8% did not move with itABBV +1.2 · MRK +1.0 · JNJ +0.6 · LLY −2.0
2 Oct 27, 2025+10.93%
Before our storiesgroup +0.1%, did not move with it
2Oct 27, 2025+10.93%
Before our stories
+0.1% did not move with itMRK +0.6 · LLY +0.1 · ABBV +0.0 · JNJ −0.1
3 Dec 22, 2025+5.81%
Before our storiesgroup +0.5%, did not move with it
3Dec 22, 2025+5.81%
Before our stories
+0.5% did not move with itMRK +3.6 · ABBV +0.5 · LLY +0.5 · JNJ +0.5
4 Jan 14, 2026+5.53%
Before our storiesgroup +1.4%, did not move with it
4Jan 14, 2026+5.53%
Before our stories
+1.4% did not move with itMRK +2.5 · JNJ +2.3 · ABBV +0.5 · LLY −0.4
5 Feb 2, 2026+5.81%
Before our storiesgroup +1.4%, did not move with it
5Feb 2, 2026+5.81%
Before our stories
+1.4% did not move with itMRK +2.8 · JNJ +1.5 · ABBV +1.2 · LLY +0.7
6 Feb 19, 2026+6.40%
Before our storiesgroup +0.2%, did not move with it
6Feb 19, 2026+6.40%
Before our stories
+0.2% did not move with itJNJ +0.8 · LLY +0.3 · MRK +0.2 · ABBV −1.9
7 Mar 9, 2026+5.69%
Before our storiesgroup +1.0%, did not move with it
7Mar 9, 2026+5.69%
Before our stories
+1.0% did not move with itLLY +1.8 · MRK +1.1 · JNJ +0.9 · ABBV −1.2
8 Mar 16, 2026+5.14%
Before our storiesgroup +0.6%, did not move with it
8Mar 16, 2026+5.14%
Before our stories
+0.6% did not move with itABBV +0.8 · JNJ +0.7 · LLY +0.4 · MRK −0.2
9 Mar 27, 2026−5.08%
Before our storiesgroup −0.1%, did not move with it
9Mar 27, 2026−5.08%
Before our stories
−0.1% did not move with itLLY −2.1 · ABBV −0.8 · JNJ +0.5 · MRK +0.6
10 Mar 31, 2026+5.95%
Before our storiesgroup +1.9%, did not move with it
10Mar 31, 2026+5.95%
Before our stories
+1.9% did not move with itLLY +3.7 · ABBV +2.0 · MRK +1.9 · JNJ +0.8
11 Apr 13, 2026+7.61%
Before our storiesgroup −0.9%, did not move with it
11Apr 13, 2026+7.61%
Before our stories
−0.9% did not move with itJNJ −0.2 · ABBV −0.7 · MRK −1.1 · LLY −1.1
12 Apr 21, 2026−5.27%
Before our storiesgroup −1.9%, did not move with it
12Apr 21, 2026−5.27%
Before our stories
−1.9% did not move with itMRK −3.9 · JNJ −2.0 · LLY −1.8 · ABBV +0.7
13 Jun 8, 2026+11.28%
Before our storiesgroup −0.7%, did not move with it
13Jun 8, 2026+11.28%
Before our stories
−0.7% did not move with itLLY +1.6 · JNJ −0.3 · MRK −1.1 · ABBV −1.8
14 Jun 9, 2026−10.83%
Before our storiesgroup +0.6%, did not move with it
14Jun 9, 2026−10.83%
Before our stories
+0.6% did not move with itLLY −0.4 · MRK +0.1 · ABBV +1.1 · JNJ +2.1
15 Jun 22, 2026+9.61%
Nothing on IDYAgroup +1.3%, did not move with it
15Jun 22, 2026+9.61%
Nothing on IDYANo IDYA story, brief or results filing in our record that day
+1.3% did not move with itABBV +6.3 · MRK +1.4 · JNJ +1.3 · LLY +0.3
16 Jul 8, 2026−6.29%
Nothing on IDYAgroup −1.5%, did not move with it
16Jul 8, 2026−6.29%
Nothing on IDYANo IDYA story, brief or results filing in our record that day
−1.5% did not move with itMRK −2.2 · LLY −1.6 · JNJ −1.4 · ABBV −0.8
17 Aug 25, 2026+6.09%
Nothing on IDYAgroup +0.3%, did not move with it
17Aug 25, 2026+6.09%
Nothing on IDYANo IDYA story, brief or results filing in our record that day
+0.3% did not move with itMRK +3.8 · ABBV +0.5 · JNJ +0.0 · LLY −1.1
18 Sep 23, 2026−5.67%
Nothing on IDYAgroup −0.8%, did not move with it
18Sep 23, 2026−5.67%
Nothing on IDYANo IDYA story, brief or results filing in our record that day
−0.8% did not move with itMRK −1.9 · LLY −1.6 · ABBV −0.1 · JNJ −0.0
19 Oct 13, 2026−4.99%
Nothing on IDYAgroup −2.4%, did not move with it
19Oct 13, 2026−4.99%
Nothing on IDYANo IDYA story, brief or results filing in our record that day
−2.4% did not move with itJNJ −5.7 · ABBV −2.4 · MRK −2.4 · LLY −1.4

A story on the same day is not a cause, and a group move is not proof either. Group: the median of LLY, JNJ, ABBV and MRK that day, the largest companies in IDYA’s SEC industry; “moved with IDYA” means the same direction and at least half the size.

What’s next · results

Before the next report: what the first day after the last four did

Six trading days after each results filing (SEC 8-K, Item 2.02). IDYA reports during the trading day, so day 1 is that day’s close. 3 of 4 times, day 6 ended on the same side as day 1.

Reported Nov 4, 2025

day 1−2.81%day 6+2.07%

Reported Feb 17, 2026

day 1+1.62%day 6+5.95%

Reported May 5, 2026

day 1−0.35%day 6−2.70%

Reported Aug 4, 2026

day 1+2.01%day 6+4.07%

Next report: expected early NovemberEstimated from the dates of its last four results filings. Not announced. Since the Aug 4 report: −7.20%. Four reports is a small sample.

Every report since 2023 →

Each line is IDYA’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.

The numbers · FY2025, filed

SEC EDGAR

Market cap$3.2B

Revenue$218.7M+3024.40%

Net income$-113.7M

EPS, diluted$-1.28+61.90%

Operating margin-72.8%

Return on equity-11.1%

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$3.2B

Enterprise Value$3.1B

Income$-113.7M

Sales$218.7M

Book/sh$10.60

Cash/sh$1.18

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio—

Current Ratio11.34

Debt/Eq—

EPS (ttm)$-1.28

EPS this Y61.9%

EPS past 3/5Y—

Sales past 3/5Y62.5%

EPS Y/Y TTM61.9%

Sales Y/Y TTM3024.4%

Shs Outstand96.49M

ROA-10.2%

ROE-11.1%

ROIC-17.5%

Gross Margin—

Oper. Margin-72.8%

Profit Margin-52.0%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$27.9M

FY21

$50.9M

FY22

$23.4M

FY23

$7.0M

FY24

$218.7M

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$27.9M	$50.9M	$23.4M	$7.0M	$218.7M
Gross Profit	—	—	—	—	—
Operating Income	$-50.3M	$-62.5M	$-134.4M	$-327.0M	$-159.3M
Net Income	$-49.8M	$-58.7M	$-113.0M	$-274.5M	$-113.7M
Diluted EPS	$-1.41	$-1.42	$-1.96	$-3.36	$-1.28
Operating Cash Flow	$-55.8M	$-87.2M	$-115.2M	$-247.6M	$-71.1M
Free Cash Flow	$-58.4M	$-90.6M	$-117.6M	$-251.4M	$-73.5M

Same industry

IDYA against four drug peers, a year at 100

IDYA is up 12.3% in a year. Merck is up 72.1%, Eli Lilly 56.6%, Johnson & Johnson 32.3% and AbbVie 24.3%. All four did more. Weekly closes, Oct 17, 2025 = 100, on a log scale, so the same percentage move is the same height on every line.

Share this chart

IDYA +12.3%. Merck +72.1%, Eli Lilly +56.6%, Johnson & Johnson +32.3%, AbbVie +24.3%. Weekly closes, Oct 17, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in IDYA’s SEC industry (Pharmaceutical Preparations) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

Same industry

In the screener →

LLY$1.18T JNJ$615.9B ABBV$504.4B MRK$360.1B ABT$181.5B PFE$168.6B VRTX$126.7B BMY$122.1B

Follow the news. Track the move.

IDYA story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Earnings

Oct 19

IDEAYA and Servier present three-trial darovasertib data at ESMO 2026

IDEAYA Biosciences and Servier presented ESMO 2026 data from three darovasertib trials in metastatic uveal melanoma. The results broaden the drug’s potential patient population, but clinical development and commercialization remain dependent on subsequent trial and regulatory milestones.

Price history unavailable

PR Newswire · 5h ago

View both sides →